Topic Listing for TECOGEN INC.

Achievements Addenda
Additional Provisions Administration
Administration Plan Adverse Events Field Gene Therapy Damage Public Perception
Amended Restated License Agreement Amended Restated Manufacturing Agreement
Amendment Amendment Targeted Genetics Stock Incentive Plan
Amendment Termination Plan Amendments Articles Incorporation
Amsterdam Molecular Therapeutics Amyotrophic Lateral Sclerosis
Annual Meeting Shareholders Annual Report Form 10-k
Application New Accounting Standards Audit Committee Report
Audit Report Prepared Independent Registered Public Accounting Firm Audits
Authority Board Directors Authorized Capital
Available Information Awards Plan
Basis Presentation Because Product Candidates Involve New Unproven Technologies Regulatory
Beneficial Ownership Reporting Compliance Biogen Idec
Biographical Information Board Committee Attendance Meetings
Board Committee Meetings Board Committees
Board Directors Recommends Vote Election Davie Hawley Business Overview
Business Strategy Bylaws
Canyon Park East Capital Requirements
Cash Equivalents Celladon
Celladon Collaboration Certain Definitions
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Relationships Related-person Transactions Certain Restrictions
Certification Cgmp3 Pre-bulk Drug Substance
Change Vote After Delivered Proxy Clinical Trials Delayed Suspended Terminated Unable Develop Product
Clinical Trials Delayed Unable Develop Product Candidates Timely Code Conduct
Code Ethics Collaboration Grant Funding
Collaborative Agreements Collaborative Other Agreements
Commitments Committees
Common Stock 001 Par Value Compensation Committee Interlocks Insider Participation
Competition Concentration Ownership Common Stock Give Certain Shareholders Significant
Condensed Quarterly Financial Information Conference Call Today 500
Conference Call Webcast Information Confidential Treatment Requested
Confidentiality Congestive Heart Failure
Consent Independent Registered Public Accounting Firm Consolidated Statements Operations
Consolidation Merger Etc Contents Proxy Statement Different Those Last
Continuing Directors Contractual Commitments Long-term Debt Obligations
Controls Procedures Corporate Governance
Corporate Governance Documents Corporate Transactions
Critical Accounting Policies Estimates Assumptions Cumulative Voting
Cystic Fibrosis Foundation Definitions
Department Defense Description Business
Description Plan Designation Rights Preferences Series Participating Cumulative Preferred Stock
Designation Series Participating Cumulative Preferred Stock Director Attendance Annual Meeting Shareholders
Director Compensation Director Independence
Director Nomination Process Directors
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Disclaimer Warranty Indemnification Disclosure Released Materials
Dispute Resolution Dividend Equivalents
Dividends Dividends Distributions
Documents Incorporated Reference Duration
Duration Amendments Earnings Per Share
Ecitals Effect Corporate Transaction
Effective 2009 Election Directors
Eligibility Receive Awards Emerald Gene Systems Ltd
Employee Retirement Plan Employees
Entitled Vote Annual Meeting Equity Compensation Plan Information
Equity Ownership Executives Not Formal Stock Requirement Executive Estimated Restructure Charges Associated Bothell Facility
Estimated Restructuring Charges Associated Bothell Facility Estimates
Exact Name Registrant Specified Charter Exclusive Sublicense Agreement
Execution Execution Copy
Executive Compensation Executive Officers
Expect Continue Operate Loss Never Become Profitable Expect Unable Comply Minimum Requirements Quotation Nasdaq Capital
Explanatory Failure Recruit Subjects Delay Prevent Clinical Trials Potential
Fair Value Fair Value Financial Instruments
Fees Financial Statement Schedules
Financial Statements Form 10-k
Form 10-q Former Biogen Collaboration
Former Name Address Changed Since Last Report Forward-looking Statements
Fractional Shares General
Genzyme Gmp3 Evelopment Lan
Goodwill Goodwill Other Intangible Assets
Goodwill Purchased Intangibles Governmental Regulation
Greement Hazardous Materials Exposes Liability Risks Regulatory Limitations Either
Healthcare Reform Measures Unwillingness Third-party Payors Provide Adequate Heart Failure
Hiv Aids Vaccine Huntingtons Disease
Impact New Accounting Pronouncements Income Taxes
Incorporation Increase Number Authorized Shares Common Stock
Independent Registered Public Accounting Firm Index Exhibits
Inflammatory Arthritis Infringement Litigation
Intense Competition Rapid Technological Change Market Result Failure International Aids Vaccine Initiative
International Aids Vaccine Initiative Agreement Interpretation
Introduction Investment Chromos Molecular Systems Inc
Investments Investor Media Contact
Issuance Preferred Stock Series Issuance Shares
Key Employees Lebers Congenital Amaurosis
Legal Proceedings License Agreement
License Grant Celladon License Grants Diligence
Limitation Director Liability Liquidation Rights
Liquidity Capital Resources Liquidity Managements Plans
List Creditors List Omitted Exhibits
Litigation Involving Intellectual Property Product Liability Other Claims Long-term Obligations
Lose Collaborative Partners Not Receive Funding Anticipate Agreements Lose Collaborative Partners Unable Develop Potential Products
Market Fluctuations Volatility Cause Price Common Stock Decline Market Registrants Common Equity Related Shareholder Matters Issuer
Name Person Filing Proxy Statement Other Registrant National Institute Allergy Infectious Diseases
Net Loss Per Common Share Ninth Amendment Continuation Lease Agreement
Nominees Non-competitive Tgc Product Rights
Nonqualified Deferred Compensation Not Provide Plans Named Executive Nontransferability Awards
Not Able Obtain Maintain Additional Party Relationships Necessary Not Able Obtain Maintain Additional Third-party Relationships Necessary
Not Attract Retain Qualified Personnel Unable Develop Commercialize Not Develop Adequate Development Manufacturing Sales Marketing Distribution
Not Receive New Funding Collaborative Agreements Grants Unable Not Retain Existing Personnel Attract Qualified Future Unable
Notice 2008 Annual Meeting Shareholders Notice 2009 Annual Meeting Shareholders
Number 0-23930 Number Awards Granted
Off-balance Sheet Arrangements Olive Way Suite 100
Operating Expenses Operating Leases
Other Assets Other Business
Other Comprehensive Loss Other Income Expense
Other Information Overview
Part Other Information Parties Not Perform Contractually Required Otherwise Expected Connection
Partners Scientific Consultants Terminate Reduce Delay Relationships Them Patent Maintenance Reimbursement
Patents License Agreements Proprietary Rights Payment Option Shares
Pays Cost Soliciting Votes Annual Meeting Penn Licensed Products Intended Shall Considered Product Purposes
Penn Patent Rights Penns Name Independent Contractor
Performance Goals Post-approval Manufacturing Product Problems Failure Satisfy Applicable Regulatory
Power Attorney Preemptive Rights
Prepaid Expenses Other Primary Product Development Programs
Principal Accountant Fees Services Product Candidates Early-stage Clinical Trials Preclinical Development Partners
Product Candidates Early-stage Clinical Trials Preclinical Development Unable Product Candidates Never Achieve Market Acceptance Even Obtain
Product Candidates Preclinical Development Early-stage Clinical Trials Partners Properties
Property Equipment Proposal Election Directors
Proposal Ratification Selection Independent Registered Public Accounting Firm Protection Against Dilution
Proxy Statement 2008 Annual Meeting Shareholders Proxy Statement Pursuant Securities Exchange Act 1934 Amendment
Purpose Purpose Powers
Quantitative Qualitative Disclosures Market Risk Ranking
Reacquired Shares Recent Reductions Force Harm Business
Recently Issued Accounting Standards Recitals
Reclassifications Redemption Sinking Fund
Registered Office Agent Regulatory Approval Process Product Candidates Costly Time-consuming Subject
Related-person Transactions Rely Parties Conduct Preclinical Research Clinical Trials Not
Remainder Page Intentionally Left Blank Replay Access
Report Independent Registered Public Accounting Firm Research Development Costs
Research Development Expenses Reserved Shares
Restricted Stock Units Revenue
Revenue Recognition Collaborative Agreements Revenue Recognition Policy
Reverse Stock Split Risks Related Common Stock
Safe Harbor Statement Private Securities Litigation Reform Act Sarbanes-oxley Act 2002
Schedule Seattle Washington 98101
Securities Authorized Issuance Equity Compensation Plan Security Ownership Certain Beneficial Owners Management Related Shareholder
See Accompanying Notes Consolidated Financial Statements Sell Additional Shares Stock Price Decline Result Dilution
Senior Management Employment Agreement Seventh Amendment Lease Agreement
Severability Shall Mean
Shareholder Communications Board Directors Shareholder Proposals 2009 Annual Meeting
Shareholder Proposals 2010 Annual Meeting Shareholder Rights Plan
Shareholders Equity Shares Subject Plan Share Limits
Signature Page Follows Signatures
Significant Revenue Relationships Concentration Risk Significant Sources Revenue
Sirna Therapeutics Sirna Therapeutics Collaboration
Special Meetings Shareholders Special Voting Requirements
Stock Appreciation Rights Stock Based Compensation
Stock Compensation Stock Grants Units
Stock Options Stock Purchase Warrants
Stock-based Compensation Sublicenses
Submission Matters Vote Security Holders Subsequent Events
Subsidiaries Targeted Genetics Corporation Success Clinical Trials Preclinical Studies Not Indicative Results
Supersedes Replaces Collaboration Agreement Table Contents
Targeted Genetics Corporation Targeted Genetics Corporation 1100 Olive Way Suite 100
Targeted Genetics Corporation Reports 2009 Financial Results Targeted Genetics Corporation Stock Incentive Plan
Tax Aspects Tem Financial Statements Supplementary Data
Tenant Term Termination
Termination Prior Change Control Terms Conditions Stock Appreciation Rights
Terms Conditions Stock Units Tgc Licensed Technology
Tgc Shall Provide Celladon Designee Tgc Shall Provide Celladon Designee Existing Analytical Methods
Trustees University Pennsylvania Unable Adequately Protect Proprietary Rights Domestically Overseas Limit
Unable Comply Minimum Requirements Quotation Nasdaq Capital Market Unable Obtain Maintain Additional Third-party Relationships Necessary Develop
Unable Obtain Maintain Licenses Necessary Third-party Technology Acceptable Unable Raise Additional Capital Needed Conduct Operations Develop
Unable Raise Additional Capital Secure Sources Funding Very Unable Raise Sufficient Additional Capital Secure Sources Funding
United States Vote Required Business Combinations
Votes Counted Votes Withheld Abstentions Treated
Voting Voting Rights
Washington 20549 What Constitutes Quorum
What Effect Not Voting What Purpose Annual Meeting
What Recommendation Board Directors What Voting Requirements Elect Directors Approve Other Proposal
What Voting Requirements Elect Directors Approve Other Proposals Withholding Taxes
Words Licensor Affiliates Sublicensees Shall Added After 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki